King Sues Intelliject Over EpiPen Patent Violation

Law360, New York (January 21, 2011, 3:08 PM EST) -- King Pharmaceuticals Inc. and a subsidiary are suing Intelliject Inc. for filing a new drug application that they say breaches a patent covering their EpiPen products for allergic reactions.

In a complaint lodged Wednesday in the U.S. District Court for District of Delaware, King and subsidiary Meridian Medical Technologies Inc. claim the approval of Intelliject's NDA to make and sell an epinephrine auto-injector before the 2025 expiration of the patent would substantially harm the companies.

At issue is U.S. Patent Number 7,794,432 B2, titled “Automatic injector...
To view the full article, register now.